Selexis SA and Turgut Pharmaceuticals Expand Agreement

Selexis SA and Turgut Pharmaceuticals have entered into a third commercial license agreement that provides Turgut with access to Selexis’ SUREtechnology Platform and SURE CHO-M Cell Line for the development of a high-quality biosimilar product for the treatment of two ultra-rare diseases: paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The new agreement builds on two commercial license agreements established between the companies in July 2016 to develop biosimilar products to treat inflammatory diseases and certain cancers using the SURE CHO-M Cell Lines.

Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein, including biosimilars, and provides seamless integration of the biologics development continuum, spanning discovery to commercialization. The SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. 

“At Selexis, we value our role in contributing to the success of partners like Turgut Pharmaceuticals who are working to bring additional therapeutic options to patients who are facing complex, and sometimes life-threatening, diseases,” said Marco Bocci, PhD, DPharm, Selexis vice president of licensing and business development.